With so many important issues being debated today, there are few topics that health care, legal, and economic experts agree on. But the fact that drug companies are the root cause of high prescription drug prices is one common denominator
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott issued the following statement on the Health and Human Services Office of Inspector General’s proposed rule on prescription drug rebates in Medicare: “While we are reviewing the proposed
(Washington, D.C.) —Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott released the following statement on today’s action in the House Judiciary Committee on legislation aimed at increasing competition in the prescription drug marketplace. “We applaud the House Judiciary
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott issued the following statement on the association’s public comments on the Health and Human Services Office of Inspector General’s proposed rule revising the safe harbors around prescription
(Washington, D.C.) — Today, members of the prescription drug supply and payment chain, including pharmacy benefit managers (PBMs), pharmaceutical manufacturers, pharmacies, including specialty and managed care pharmacies, and health plans, sent a letter to Vice President Mike Pence and congressional
Lawmakers Reintroduce Bill to Close Loopholes Allowing Big Drug Companies to Block Competition from More Affordable Options The Pharmaceutical Care Management Association, PCMA, applauds Senators Maggie Hassan (D-NH) and Mike Braun (R-IN) for recently reintroducing legislation, the Prescription Drug Competition Act,
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott issued the following statement on the Biden Administration’s announcement to curb drug manufacturer patent abuses. “We applaud the Biden Administration for taking real action to reduce prescription
While debating important legislative proposals that can impact patients’ health and access to medications, the discussion should rely on solid facts and evidence. Today, we’re highlighting new reputable third-party research and analyses by economists which underscore that legislation focused on
©2024 PCMA. All Rights Reserved.
